USPTO aims to fend off Fintiv challenge at SCOTUS

Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Insulin pump rivals face off in major trade secrets dispute hearing

8 January 2026 Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.

Americas

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

8 January 2026 Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.

Americas

Merchant & Gould hires 13 attorneys to open new Boston office

6 January 2026 The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.

More features

How AI will be shaped by legal and regulatory developments in 2026

Deadline extended: Who are the world’s best in-house counsel?

‘All voices must be heard’: New CIPA president sets out plans for 2026

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

USPTO aims to fend off Fintiv challenge at SCOTUS

More on this story

Editor's picks

Editor's picks

More features